- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01744106
A Multicenter Study of Pseudoephedrine for the Temporary Relief of Nasal Congestion in Children With the Common Cold
April 20, 2016 updated by: Perrigo Company
A Multicenter, Randomized, Placebo-Controlled Study of Pseudoephedrine for the Temporary Relief of Nasal Congestion in Children With the Common Cold
This study is designed to confirm the effectiveness of single-ingredient pseudoephedrine in children for the temporary relief of nasal congestion due to the common cold, an indication described under 21 CFR 341.80(b)(1).
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
565
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Anaheim, California, United States, 92804
- Emmaus Research Center
-
Costa Mesa, California, United States, 92626
- WCCT Global, LLC
-
-
Idaho
-
Boise, Idaho, United States, 83642
- Advanced Clinical Research - Boise
-
-
Kentucky
-
Louisville, Kentucky, United States, 40291
- Bluegrass Clinical Research
-
-
Nebraska
-
Omaha, Nebraska, United States, 68134
- Meridian Clinical Research
-
-
Ohio
-
Cleveland, Ohio, United States, 44122
- Rapid Medical Research
-
-
South Carolina
-
Orangeburg, South Carolina, United States, 29118
- Carolina Ear, Nose and Throat Clinic
-
-
South Dakota
-
Dakota Dunes, South Dakota, United States, 57049
- Meridian Clinical Research - Dakota Dunes
-
-
Texas
-
Waxahachie, Texas, United States, 75165
- ClinPoint Trials, LLC
-
-
Utah
-
St. George, Utah, United States, 84790
- Chrysalis Clinical Research
-
West Jordan, Utah, United States, 84088
- Advanced Clinical Research - West Jordan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 11 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female subjects, ages 6 through 11 years, are experiencing the common cold, but are otherwise healthy.
- Subjects have an onset of cold symptoms within the past 2.5 days before screening and are experiencing self-reported nasal congestion of at least stuffy severity (score = 3 or 4).
- Subjects have at least two of the following additional symptoms due to common cold: runny nose, sneezing, sore throat, headache, body achiness, and cough, as deemed by the parent.
- Subjects can swallow oral tablets without chewing them (based on a pretest of successfully swallowing a placebo tablet at screening)
- Findings from the medical history review and vital signs are within the range of clinical acceptability, as determined by the investigator.
- Subject and legally authorized representative are likely to be compliant and complete the study.
- Subject's legally authorized representative has signed and dated the informed consent form. Subject has given verbal assent, and has signed and dated the informed assent form.
- Female subjects who have reached menarche must have a negative urine pregnancy test at screening. These subjects must have practiced abstinence for at least three months prior to study entry and for the duration of the study. A second pregnancy test will be given when the subject returns to the clinic after the last dose.
- Subject and legally authorized representative can read and understand English.
- Subject's legally authorized representative who signs informed consent is available to administer all assessments and study medication on days 1 and 2.
Exclusion Criteria:
- Have any of the following medical conditions: heart disease, high blood pressure, thyroid disease, diabetes, peripheral vascular disease, increased intraocular pressure, prostatic hypertrophy
- Are under treatment for a hyperexcitability disorder with a medication regimen that has not been stable for at least 3 months
- Are currently experiencing an asthmatic episode
- Are experiencing symptoms of seasonal or perennial allergic rhinitis
- Are currently or within the last 24 hours having symptoms of vomiting or diarrhea
- Have been exposed to immediate family members with the flu within the past week
- Are exhibiting signs or symptoms of, or diagnosed with sinusitis, pneumonia, strep throat, acute otitis media, or influenza
- Are experiencing a fever 103˚F or higher at screening
- Are from homes where there is smoking in the home around the child.
- Are currently taking a monoamine oxidase inhibitor (MAOI), or have taken a MAOI within two weeks of screening (e.g., isocarboxazid - Marplan, phenelzine - Nardil, selegiline - Eldepryl, Emsam, Zelapar, and tranylcypromine - Parnate). Note: subjects may not discontinue taking a MAOI solely of the purposes of qualifying for the study.
- Have a known sensitivity or allergy to pseudoephedrine, phenylephrine, or acetaminophen or any of the excipients of the drug product
- Have taken any oral cold or allergy medicine within 12 hours of enrollment, or intranasal decongestants within 24 hours of enrollment except for single-ingredient OTC analgesics
- Have the need to take additional medications, including cough and cold (i.e., oral or intranasal antihistamines, intranasal steroids, intranasal decongestants), or herbal/dietary supplements during the study, with the exception of acetaminophen, a medication regimen for a hyperexcitability disorder that has been stable for at least three months or a daily vitamin or multivitamin/multimineral supplement
- Have participated in another clinical study within 30 days before entry
- Have another child from the household currently participating in this study
- Have a history of drug, alcohol, or tobacco use (older children)
- Are involved directly or indirectly with the conduct and administration of this study (i.e., children of principal investigator, subinvestigator, study coordinators, other study personnel, employees of Perrigo, and the families of each).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: pseudoephedrine hydrochloride 30 mg tablets
Test product
|
|
Placebo Comparator: placebo tablets
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nasal Congestion Severity (NCSi) (instantaneous) scores
Time Frame: 1 Day
|
Weighted sum of change from baseline in Nasal Congestion Severity (NCSi) (instantaneous) scores over the first eight hours of treatment on Day 1
|
1 Day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change from baseline in NCSi scores from 0 to 4 hours
Time Frame: Day 1
|
Sum of change from baseline in NCSi scores from 0 to 4 hours after the first dose on Day 1
|
Day 1
|
change from baseline in NCSi scores from 6, 7, and 8 hours
Time Frame: Day 1
|
Weighted sum of change from baseline in NCSi scores from 6, 7, and 8 hours after the first dose on Day 1
|
Day 1
|
Nasal Congestion Relief (NCR) reflective scores at 4 hours and 8 hours
Time Frame: Day 1
|
Sum of Nasal Congestion Relief (NCR) reflective scores at 4 hours and 8 hours on Day 1
|
Day 1
|
NCSi score at each time point from 0 to 8 hours
Time Frame: Day 1
|
NCSi score at each time point from 0 to 8 hours after the first dose on Day 1
|
Day 1
|
NCSr (reflective) scores at 6 hours and 12 hours
Time Frame: Day 2
|
Sum of NCSr (reflective) scores at 6 hours and 12 hours on Day 2
|
Day 2
|
NCSr scores at 6 and 12 hours
Time Frame: Day 2
|
NCSr scores at 6 and 12 hours on Day 2
|
Day 2
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change from baseline in the Nasal Symptom and Function (NSF) composite score of NCSi
Time Frame: Day 1
|
Weighted sum of change from baseline in the Nasal Symptom and Function (NSF) composite score of NCSi, nasal breathing, and nasal clearing over the first eight hours of treatment on Day 1
|
Day 1
|
Sum of change from baseline in NSF composite score from 0 to 4 hours
Time Frame: Day 1
|
Sum of change from baseline in NSF composite score from 0 to 4 hours after the first dose on Day 1
|
Day 1
|
Weighted sum of change from baseline in NSF composite score from 6, 7, and 8 hours
Time Frame: Day 1
|
Weighted sum of change from baseline in NSF composite score from 6, 7, and 8 hours after the first dose on Day 1
|
Day 1
|
morning sleep score on Days 2 through 7
Time Frame: Day 7
|
Change from baseline in morning sleep score on Days 2 through 7
|
Day 7
|
NSF composite score on Days 2 through 7
Time Frame: Day 7
|
Change from baseline in NSF composite score on Days 2 through 7
|
Day 7
|
NSF + S (sleep) composite score on Days 2 through 7
Time Frame: Day 7
|
Change from baseline in the NSF + S (sleep) composite score on Days 2 through 7
|
Day 7
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2012
Primary Completion (Actual)
April 1, 2016
Study Completion (Actual)
April 1, 2016
Study Registration Dates
First Submitted
December 4, 2012
First Submitted That Met QC Criteria
December 5, 2012
First Posted (Estimate)
December 6, 2012
Study Record Updates
Last Update Posted (Estimate)
April 22, 2016
Last Update Submitted That Met QC Criteria
April 20, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Picornaviridae Infections
- Common Cold
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Central Nervous System Stimulants
- Sympathomimetics
- Vasoconstrictor Agents
- Nasal Decongestants
- Ephedrine
- Pseudoephedrine
Other Study ID Numbers
- PRGO-PSE-09001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nasal Congestion Associated With the Common Cold
-
Church & Dwight Company, Inc.Evidilya S.r.l.RecruitingNasal Congestion | Common ColdItaly
-
Larena SASBioFortisCompleted
-
Church & Dwight Company, Inc.CompletedNasal CongestionPoland
-
McNeil ABCompletedHeadache | Nasal Congestion | Common ColdBelgium
-
NovartisCompletedCommon Cold Associated With CoughCanada
-
Chordate MedicalCompletedNasal Congestion | Non-allergic RhinitisFinland, Italy, United Kingdom, Greece, Netherlands, Czechia
-
Ache Laboratorios Farmaceuticos S.A.Withdrawn
-
Abbott Medical DevicesBaim Institute for Clinical ResearchWithdrawnWith de Novo or Restenotic Lesions in the Common and/or External Iliac Arteries
-
Hong Kong Baptist UniversityThe Hong Kong Jockey Club Charities TrustCompletedCommon Cold | Preventive Effectiveness | Elderly With Qi-deficiency Constitution | The Individualized Jade Wind-Barrier Herbal Tea Bag | Pragmatic Randomized Controlled TrialChina
-
Lannett Company, Inc.CompletedAny Ear Nose or Throat Conditions | With Identified Need for a Diagnostic Procedure or Surgery on or Through the Mucous Membranes of the Nasal CavitiesUnited States
Clinical Trials on Placebo tablets
-
Centre of Clinical Pharmacology, Hanoi Medical...Not yet recruitingIrritable Bowel Syndrome With DiarrheaVietnam
-
Galapagos NVCompletedCrohn's DiseaseUnited Kingdom, Belgium, France, Hungary, Russian Federation, Czech Republic, Germany, Poland, Romania
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Otsuka Beijing Research InstituteRecruitingIrritable Bowel Syndrome of Diarrhea Type (IBS-D)China
-
Jiangsu vcare pharmaceutical technology co., LTDRecruitingModerate to Severe Atopic DermatitisChina
-
Akros Pharma Inc.CompletedSkin Diseases | Psoriasis | Plaque PsoriasisUnited States, Canada, Poland
-
JKT Biopharma Co., Ltd.Recruiting
-
Ascletis Pharmaceuticals Co., Ltd.Recruiting
-
Sunshine Lake Pharma Co., Ltd.CompletedDiabetic NephropathyChina